Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of
3 months ago
- #HIV-1
- #antiretroviral therapy
- #clinical trial
- Study evaluates switching to doravirine (100 mg) and islatravir (0.25 mg) from bictegravir, emtricitabine, and tenofovir alafenamide in HIV-1 patients.
- Phase 3, randomized, double-blind, non-inferiority trial conducted across 49 sites in six countries.
- Participants were virologically suppressed adults with HIV-1, randomized 2:1 to switch or continue current treatment.
- Primary endpoint: viral load ≥50 copies/mL at week 48; doravirine/islatravir showed non-inferiority (1.5% vs 0.6%).
- Adverse event rates were similar between groups, with no deaths reported.
- Doravirine/islatravir offers a two-drug, once-daily, single-tablet option without an integrase inhibitor.